Study of the MonarQ System for Leaky Tricuspid Valve
Part of Heart & circulation clinical trials.
This study tests a new device called the MonarQ TTVR System, which is placed through a small tube in a blood vessel to fix a leaky tricuspid valve without open-heart surgery. It is for people with severe tricuspid regurgitation symptoms that are not relieved by heart failure medicines alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tricuspid valve must have severe or greater leakage that is causing symptoms
- Your heart failure must be well controlled with standard treatments
- You must not need emergency heart surgery or have any heart surgery planned within the next year
- You must not have advanced heart failure that requires a pump or transplant
- You cannot be in another clinical trial for a drug, device, or biologic study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new device to fix a leaky tricuspid valve without open-heart surgery. It is for people with severe leakage who are considered too high-risk for traditional surgery.
This study tests a new device to help people with severe tricuspid regurgitation (leaky heart valve) who are at higher risk from surgery. It aims to see if the device can reduce the leak and improve symptoms.
This trial tests a new device called the Laplace system, which replaces the tricuspid valve in your heart without open-heart surgery. It is designed for people with severe tricuspid regurgitation (a leaky heart valve) who still have symptoms despite taking medications.
This trial tests a new device that replaces a leaky tricuspid valve (a heart valve) without open-heart surgery. If your tricuspid valve isn't working well and medicines haven't helped enough, this procedure might improve your heart function and symptoms.
This trial tests a new device called TricValve, which is placed through a catheter (a thin tube) to fix a leaky tricuspid valve on the right side of the heart. It aims to reduce blood flowing backward and improve heart failure symptoms for people who can't have open-heart surgery and haven't been helped by other catheter treatments.
This study tests a new, catheter-based procedure to treat moderate-to-severe leaking of the tricuspid valve (a heart valve on the right side). It’s for people who are high surgical risk and might benefit from replacing the valve without open-heart surgery.
Hear when a new Tricuspid Valve Regurgitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.